These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1556 related items for PubMed ID: 23866358
1. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience. Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358 [Abstract] [Full Text] [Related]
2. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW, Barillari G. J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983 [Abstract] [Full Text] [Related]
5. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Lip GY, Larsen TB, Skjøth F, Rasmussen LH. J Am Coll Cardiol; 2012 Aug 21; 60(8):738-46. PubMed ID: 22575324 [Abstract] [Full Text] [Related]
6. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C. Int Angiol; 2012 Aug 21; 31(4):330-9. PubMed ID: 22801398 [Abstract] [Full Text] [Related]
7. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P, Working Group on Perioperative Haemostasis. Arch Cardiovasc Dis; 2013 Aug 21; 106(6-7):382-93. PubMed ID: 23810130 [Abstract] [Full Text] [Related]
8. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Thromb Haemost; 2012 Mar 21; 107(3):584-9. PubMed ID: 22186961 [Abstract] [Full Text] [Related]
12. Bleeding and antidotes in new oral anticoagulants. Majeed A, Schulman S. Best Pract Res Clin Haematol; 2013 Jun 21; 26(2):191-202. PubMed ID: 23953907 [Abstract] [Full Text] [Related]
13. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis. Alotaibi G, Alsaleh K, Wu C, Mcmurtry MS. Int Angiol; 2014 Aug 21; 33(4):301-8. PubMed ID: 25056161 [Abstract] [Full Text] [Related]
15. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. Nieto JA, Espada NG, Merino RG, González TC. Thromb Res; 2012 Aug 21; 130(2):183-91. PubMed ID: 22425218 [Abstract] [Full Text] [Related]